Pulse Biosciences (NASDAQ:PLSE) Issues Quarterly Earnings Results

Pulse Biosciences (NASDAQ:PLSE) posted its earnings results on Thursday. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.01), Zacks reports. The business had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.52 million. Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. The company’s revenue for the quarter was down 54.1% on a year-over-year basis. During the same period last year, the business posted ($0.29) EPS.

Here are the key takeaways from Pulse Biosciences’ conference call:

• Pulse completed enrollment in its NANOPULSE-AF pivotal study with 169 evaluable patients, three months ahead of its original schedule. Patients are now in follow-up, with blended six- and 12-month results expected in Q3 2027.
• Preliminary PRECISE-BTN results showed that a single Vybrance treatment reduced thyroid nodule volume by more than 50% in 86% of patients, with a 78% average improvement in quality-of-life scores at six months and no serious adverse events reported. Further follow-up is due in 2027 and will support a planned 510(k) submission.
• The company ended the quarter with $189.2 million in cash and marketable securities, which management says provides roughly two years of runway; about $64 million of ATM capacity remains. It plans to use capital for clinical programs and manufacturing and commercial-launch preparation.
• Q3 revenue was just $395,000, while GAAP net loss widened to $23.1 million from $19.4 million a year earlier. Management expects quarterly non-GAAP costs and expenses to rise 15%–25% above the roughly $20 million average in Q2 and Q3 as clinical and pre-commercial investment increases.
• Pulse is preparing manufacturing capacity and market-launch plans for its nPulse catheter, targeting launch readiness beginning in early 2028 and remaining open to a partnership or other launch structure. However, strategic discussions have not produced a disclosed deal, and management said partners are waiting for further clinical and regulatory evidence.

Pulse Biosciences Price Performance

PLSE traded up $0.22 during trading on Friday, hitting $53.29. The stock had a trading volume of 428,197 shares, compared to its average volume of 373,557. The stock has a 50 day simple moving average of $51.55 and a two-hundred day simple moving average of $32.28. Pulse Biosciences has a twelve month low of $12.56 and a twelve month high of $58.90.

Insider Activity

In other Pulse Biosciences news, COO Liane Teplitsky acquired 1,036 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The stock was purchased at an average price of $48.23 per share, for a total transaction of $49,966.28. Following the acquisition, the chief operating officer owned 1,036 shares in the company, valued at approximately $49,966.28. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders acquired 4,095 shares of company stock worth $199,931 over the last 90 days. Corporate insiders own 74.00% of the company’s stock.

Trending Headlines about Pulse Biosciences

Here are the key news stories impacting Pulse Biosciences this week:

• Positive Sentiment: Six-month interim results from the PRECISE-BTN study of Pulse’s nano-pulsed field ablation treatment for thyroid nodules were described as positive. The update adds clinical evidence for the technology. Article: Pulse Biosciences’ NsPFA Treatment Shows Positive Six-Month Thyroid Study Results Article: Six-Month PRECISE-BTN Study Results
• Positive Sentiment: Canaccord Genuity raised its price target from $58 to $74 and maintained a Buy rating; Needham also reiterated Buy and raised its target from $58 to $64. These higher targets reflect improved analyst expectations. Canaccord Genuity recommendations Needham recommendations
• Positive Sentiment: The company said it completed enrollment in its U.S. pivotal IDE study in six months, three months ahead of schedule—progress toward advancing its technology. Business updates and Q3 results
• Negative Sentiment: Pulse plans a 15%–25% increase in quarterly non-GAAP expenses as it works toward a Q4 2027 CE Mark target. The added spending could weigh on cash use and future losses. Expense outlook and CE Mark target
• Negative Sentiment: Q3 revenue was $400,000, below the approximately $521,000 estimate and down 54.1% year over year. The $0.32 per-share loss was also slightly wider than the $0.31 consensus loss, underscoring the company’s limited current revenue base. Q3 results coverage

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on PLSE. Needham & Company LLC upped their price target on shares of Pulse Biosciences from $58.00 to $64.00 and gave the stock a “buy” rating in a research report on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Thursday, October 15th. Mizuho set a $65.00 target price on Pulse Biosciences in a report on Friday. Oppenheimer lifted their price target on Pulse Biosciences from $35.00 to $60.00 and gave the company an “outperform” rating in a report on Tuesday, October 13th. Finally, BTIG Research assumed coverage on Pulse Biosciences in a research report on Wednesday, September 23rd. They issued a “buy” rating and a $70.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $66.60.

About Pulse Biosciences

Pulse Biosciences, Inc (NASDAQ:PLSE) is a medical technology company developing bioelectric therapies based on its Nano-Pulse Stimulation (NPS) technology. The technology uses short, high-voltage electrical pulses to create temporary openings in cell membranes, with the goal of selectively affecting targeted cells while limiting thermal damage to surrounding tissue.

The company’s principal product is the CellFX System, a device designed to deliver NPS treatments for certain dermatologic conditions.